About the Company
LACQ is a blank check company formed for the purpose of effecting a merger or other business combination with a target company. Leisure is led by Lorne Weiland Daniel Silversand completed its Initial Public Offering in December 2017.
Employees
7915
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LACQ News
Q4 2023 Ensysce Biosciences Inc Earnings Call
Ram Selvaraju; Analyst; H.C. Wainwright & Company Inc ...
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription ...
Ensysce Biosciences Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans SAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / ...
Ensysce Biosciences Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve ...
Ensysce Biosciences, Inc.: Ensysce Biosciences Receives Positive Nasdaq Listing Determination
SAN DIEGO, CA / ACCESSWIRE / February 27, 2024 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug ...
Ensysce Biosciences Inc (ENSC)
SAN DIEGO, CA - Ensysce Biosciences, Inc. (NASDAQ:ENSC), a biotech firm focused on enhancing prescription drug safety, has announced agreements for the immediate exercise of... SAN DIEGO, CA ...
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
SAN DIEGO, CA / ACCESSWIRE / February 21, 2024/Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription ...
Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / E ...
ENSC Ensysce Biosciences, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Loading the latest forecasts...